Skin Reactivity in Patients with Cancer
- 3 June 1971
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 284 (22), 1255-1257
- https://doi.org/10.1056/nejm197106032842210
Abstract
DEPRESSION of the delayed hypersensitivity response in patients with advanced cancer has been observed by a number of investigators.1 2 3 4 The chemical hapten 2,4-dinitrochlorobenzene (DNCB) has been used widely for studies of such patients. The response can be quantitated, and almost all normal persons can be sensitized2 , 5; in addition, use of DNCB eliminates the problem of determining whether the patient has been exposed to any of the commonly used skin-test antigens. Furthermore, the majority of patients reacting to common antigens also react to DNCB.2 A correlation between reactivity to DNCB and prognosis in patients with cancer led Eilber and Morton . . .Keywords
This publication has 10 references indexed in Scilit:
- Impaired immunologic reactivity and recurrence following cancer surgeryCancer, 1970
- Immunologic Unresponsiveness to a Contact Sensitizer in Man**From the Division of Dermatology of the Medical College of Virginia, Richmond, Va. 23219.Journal of Investigative Dermatology, 1968
- Immunologic alterations in bronchogenic cancer.Sequential StudyCancer, 1968
- Suppression of the tuberculin response in malignant disease.BMJ, 1965
- Immunological defect in aged population and its relationship to cancerCancer, 1965
- Immunologic Responses of Healthy Volunteers Receiving Azathioprine (Imuran)International Archives of Allergy and Immunology, 1965
- Delayed Hypersensitivity in VitroThe Journal of Immunology, 1964
- Abnormal cellular response to skin abrasion in cancer patientsCancer, 1963
- In vitro Cell Migration as a Model for Delayed Hypersensitivity.Experimental Biology and Medicine, 1962
- A METHOD OF STUDYING LEUKOCYTIC FUNCTIONS IN VIVOAnnals of the New York Academy of Sciences, 1955